Tetraphase Pharmaceuticals to Present at BMO Prescriptions for Success Healthcare Conference
05 déc. 2018 06h30 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Dec. 05, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
08 nov. 2018 16h01 HE
|
Tetraphase Pharmaceuticals, Inc.
XERAVATM (eravacycline) Now Available to Hospitals in the United States Conference Call Today at 4:30 p.m. Eastern Time WATERTOWN, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Tetraphase...
Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences
07 nov. 2018 06h00 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call
01 nov. 2018 16h01 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces Positive Data from Post-Hoc Analysis of Phase 3 Trials Demonstrating Efficacy of XERAVA™ (eravacycline) in Obese and Renally Impaired Patients with Complicated Intra-Abdominal Infections
23 oct. 2018 06h30 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces Commercial Launch of XERAVA™ in the United States
11 oct. 2018 16h01 HE
|
Tetraphase Pharmaceuticals, Inc.
FDA-Approved for the Treatment of Complicated Intra-Abdominal Infections Provides Broad Spectrum of Coverage Against Gram-negative, Gram-positive, and Anaerobic Bacteria for a Range of Patients with...
Tetraphase Pharmaceuticals Announces Presentation of Positive Data from Phase 3 Trials of XERAVA™ (eravacycline) and Multiple-Ascending Dose Trial of TP-6076 at IDWeek 2018
08 oct. 2018 06h30 HE
|
Tetraphase Pharmaceuticals, Inc.
XERAVA Demonstrated Efficacy in Treating Secondary Bacteremia in Patients with Complicated Intra-Abdominal Infections in Post-Hoc Analysis of Phase 3 Clinical Trials TP-6076 Demonstrated...
Tetraphase Pharmaceuticals Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
28 sept. 2018 16h01 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 28, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals to Present at the Cantor Global Healthcare Conference
24 sept. 2018 16h01 HE
|
Tetraphase Pharmaceuticals, Inc.
WATERTOWN, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat...
Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections
20 sept. 2018 13h08 HE
|
Tetraphase Pharmaceuticals, Inc.
– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) --...